1. Park HJ, Sandor K, McQueen J, Woller SA, Svensson CI, Corr M, et al. The effect of gabapentin and ketorolac on allodynia and conditioned place preference in antibody-induced inflammation. Eur J Pain 2016; 20: 917-25. PMID:
10.1002/ejp.816. PMID:
26517300. PMID:
PMC5986296.
2. Bas DB, Su J, Sandor K, Agalave NM, Lundberg J, Codeluppi S, et al. Collagen antibody-induced arthritis evokes persistent pain with spinal glial involvement and transient prostaglandin dependency. Arthritis Rheum 2012; 64: 3886-96. PMID:
10.1002/art.37686. PMID:
22933386.
4. Inceoglu B, Bettaieb A, Trindade da Silva CA, Lee KS, Haj FG, Hammock BD. Endoplasmic reticulum stress in the peripheral nervous system is a significant driver of neuropathic pain. Proc Natl Acad Sci U S A 2015; 112: 9082-7. PMID:
10.1073/pnas.1510137112. PMID:
26150506. PMID:
PMC4517273.
6. Bystrom J, Wray JA, Sugden MC, Holness MJ, Swales KE, Warner TD, et al. Endogenous epoxygenases are modulators of monocyte/macrophage activity. PLoS One 2011; 6: e26591PMID:
10.1371/journal.pone.0026591. PMID:
22028915. PMID:
PMC3197524.
7. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 1996; 78: 415-23. PMID:
10.1161/01.RES.78.3.415. PMID:
8593700.
8. Chen J, Capdevila JH, Zeldin DC, Rosenberg RL. Inhibition of cardiac L-type calcium channels by epoxyeicosatrienoic acids. Mol Pharmacol 1999; 55: 288-95. PMID:
9927620.
9. Christianson CA, Corr M, Firestein GS, Mobargha A, Yaksh TL, Svensson CI. Characterization of the acute and persistent pain state present in K/BxN serum transfer arthritis. Pain 2010; 151: 394-403. PMID:
10.1016/j.pain.2010.07.030. PMID:
20739123. PMID:
PMC2955775.
10. Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther 2013; 15(Suppl 3): S2PMID:
24267197. PMID:
PMC3891482.
11. Jhun HJ, Ahn K, Lee SC. Estimation of the prevalence of osteoarthritis in Korean adults based on the data from the fourth Korea national health and nutrition examination survey. Anesth Pain Med 2010; 3: 201-6.
14. Prus AJ, James JR, Rosecrans JA. Conditioned place preference. editors. Methods of Behavior analysis in Neuroscience. 2nd ed. In: Buccafusco JJ, Boca Raton, CRC Press. 2009. p. 96-104.
15. Xu X, Li R, Chen G, Hoopes SL, Zeldin DC, Wang DW. The role of cytochrome P450 epoxygenases, soluble epoxide hydrolase, and epoxyeicosatrienoic acids in metabolic diseases. Adv Nutr 2016; 7: 1122-8. PMID:
10.3945/an.116.012245. PMID:
28140329. PMID:
PMC5105036.
16. Park HJ, Sandor K, McQueen J, Woller SA, Svensson CI, Corr M, et al. The effect of gabapentin and ketorolac on allodynia and conditioned place preference in antibody-induced inflammation. Eur J Pain 2016; 20: 917-25. PMID:
10.1002/ejp.816. PMID:
26517300. PMID:
PMC5986296.
17. Mease P, Hanna S, Frakes EP, Altman RD. Pain mechanisms in osteoarthritis: understanding the role of central pain and current approaches to its treatment. J Rheumatol 2011; 38: 1546-51. PMID:
10.3899/jrheum.100759. PMID:
21632678.
18. Mullin CA, Hammock BD. Chalcone oxides--potent selective inhibitors of cytosolic epoxide hydrolase. Arch Biochem Biophys 1982; 216: 423-39. PMID:
10.1016/0003-9861(82)90231-4. PMID:
7114846.
19. Okun A, Liu P, Davis P, Ren J, Remeniuk B, Brion T, et al. Afferent drive elicits ongoing pain in a model of advanced osteoarthritis. Pain 2012; 153: 924-33. PMID:
10.1016/j.pain.2012.01.022. PMID:
22387095. PMID:
PMC3313555.
20. Harder DR, Campbell WB, Roman RJ. Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone. J Vasc Res 1995; 32: 79-92. PMID:
10.1159/000159080. PMID:
7537544.
21. Kanellopoulos AH, Matsuyama A. Voltage-gated sodium channels and pain-related disorders. Clin Sci (Lond) 2016; 130: 2257-65. PMID:
10.1042/CS20160041. PMID:
27815510.
22. Liu CY, Lu ZY, Li N, Yu LH, Zhao YF, Ma B. The role of large-conductance, calcium-activated potassium channels in a rat model of trigeminal neuropathic pain. Cephalalgia 2015; 35: 16-35. PMID:
10.1177/0333102414534083. PMID:
24820887.
23. Moini Zanjani T, Ameli H, Labibi F, Sedaghat K, Sabetkasaei M. The attenuation of pain behavior and serum COX-2 concentration by curcumin in a rat model of neuropathic pain. Korean J Pain 2014; 27: 246-52. PMID:
10.3344/kjp.2014.27.3.246. PMID:
25031810. PMID:
PMC4099237.
24. Wagner KM, McReynolds CB, Schmidt WK, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases. Pharmacol Ther 2017; 180: 62-76. PMID:
10.1016/j.pharmthera.2017.06.006. PMID:
28642117. PMID:
PMC5677555.
25. Iliff JJ, Wang R, Zeldin DC, Alkayed NJ. Epoxyeicosanoids as mediators of neurogenic vasodilation in cerebral vessels. Am J Physiol Heart Circ Physiol 2009; 296: H1352-63. PMID:
10.1152/ajpheart.00950.2008. PMID:
19304946. PMID:
PMC2685348.
26. Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai HJ, et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A 2006; 103: 18733-8. PMID:
10.1073/pnas.0609158103. PMID:
17130447. PMID:
PMC1693731.
27. Norwood S, Liao J, Hammock BD, Yang GY. Epoxyeicosatrienoic acids and soluble epoxide hydrolase: potential therapeutic targets for inflammation and its induced carcinogenesis. Am J Transl Res 2010; 22: 447-57. PMID:
20733953. PMID:
PMC2923867.
28. Marowsky A, Burgener J, Falck JR, Fritschy JM, Arand M. Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism. Neuroscience 2009; 163: 646-61. PMID:
10.1016/j.neuroscience.2009.06.033. PMID:
19540314.
29. McLellan GJ, Aktas Z, Hennes-Beean E, Kolb AW, Larsen IV, Schmitz EJ, et al. Effect of a soluble epoxide hydrolase inhibitor, UC1728, on LPS-induced uveitis in the rabbit. J Ocul Biol 2016 4: 10.13188/2334-2838.1000024. PMID:
10.13188/2334-2838.1000024. PMID:
28066796. PMID:
PMC5218821.